Ticker

India's drugmakers roll out low-cost copies for Novo Nordisk's semaglutide, slashing prices up to 70% as analysts weigh global market disruption risks.

Generic drugmakers face pricing pressure, but companies like TEVA, SDZNY and RDY are betting on complex generics and biosimilars to protect growth.

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #Abatacept--Dr. Reddy's announces USFDA acceptance to review its Biologics License Application (BLA) for proposed interchangeable biosimilar, Abatacept.

Bessemer Group Inc. raised its holdings in shares of Dr. Reddy's Laboratories Ltd (NYSE: RDY) by 30.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,350,988 shares of the company's stock after buying an additional 318,621 shares during the

Dr. Reddy's Laboratories (NYSE: RDY) reported a "resilient performance" in its fiscal third quarter of FY26, with revenue growth and steady profitability despite what management described as product-specific headwinds, led by lower lenalidomide sales and continued pricing pressure in U.S. and European generics. On the company's earnings call, Chief Financial Officer M.V. Narasimham (MVN) said consolidated